Notably, aberrant activation of the AKT pathway is a hallmark in many human malignancies,18, 19, 20 and this is particularly relevant in T‐ALL, where the constitutive activation of the phosphatidylinositol 3‐kinase/Protein Kinase B/mTOR (PI3K/AKT/mTOR) pathway has been observed in 70%–85% of patients, often correlating with poor clinical outcomes.21, 22, 23. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.